La imperiosa necesidad de la detección y el tratamiento precoces | 15 AGO 22

Adenocarcinoma esofágico

El cáncer de esófago (CE) es la sexta causa más común de muerte asociada al cáncer en todo el mundo, lo que representa aproximadamente 1 de cada 20 muertes por cáncer.
Autor/a: Abel Joseph, OH Siva Raja et al.  Cleveland Clinic Journal of Medicine. Volume 89 Number 5 Mayo 2022.
INDICE:  1. Texto principal | 2. Referencia bibliográfica
Referencia bibliográfica

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6):394–424. doi:10.3322/caac.21492.

2. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER* Explorer: an interactive website for SEER cancer statistics. https://seer.cancer.gov. Accessed April 22, 2022.

3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70(1):7–30. doi:10.3322/caac.21590.

4. Tian J, Zuo C, Liu G, et al. Cumulative evidence for the relationship between body mass index and the risk of esophageal cancer: an updated meta-analysis with evidence from 25 observational studies. J Gastroenterol Hepatol 2020; 35(5):730–743. doi:10.1111/jgh.14917

5. Qumseya BJ, Bukannan A, Gendy S, et al. Systematic review and meta-analysis of prevalence and risk factors for Barrett’s esophagus. Gastrointest Endosc 2019; 90(5):707–717.e1. doi:10.1016/j.gie.2019.05.030

6. Syed A, Maradey-Romero C, Fass R. The relationship between eosinophilic esophagitis and esophageal cancer. Dis Esophagus 2017; 30(7):1–5. doi:10.1093/dote/dox050

7. Anderson LA, Cantwell MM, Watson RG, et al. The association between alcohol and refl ux esophagitis, Barrett’s esophagus, and esophageal adenocarcinoma. Gastroenterology 2009; 136(3): 799–805 doi:10.1053/j.gastro.2008.12.005

8. Codipilly DC, Chandar AK, Singh S, et al. The effect of endoscopic surveillance in patients with Barrett’s esophagus: a systematic review and meta-analysis. Gastroenterology 2018; 154(8):2068-2086.e5. doi:10.1053/j.gastro.2018.02.022

9. Kastelein F, van Olphen SH, Steyerberg EW, Spaander MC, Bruno MJ; ProBar-Study Group. Impact of surveillance for Barrett’s oesophagus on tumour stage and survival of patients with neoplastic progression. Gut 2016; 65(4):548–554. doi:10.1136/gutjnl-2014-308802

10. ASGE Standards of Practice Committee, Qumseya B, Sultan S, Bain P, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc 2019; 90(3):335–359.e2. doi:10.1016/j.gie.2019.05.012

11. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011; 365(15):1375–1383. doi:10.1056/NEJMoa1103042

12. Tan MC, Mansour N, White DL, Sisson A, El-Serag HB, Thrift AP. Systematic review with meta-analysis: prevalence of prior and concurrent Barrett’s oesophagus in oesophageal adenocarcinoma patients. Aliment Pharmacol Ther 2020; 52(1):20–36. doi:10.1111/apt.15760

13. Kadri SR, Lao-Sirieix P, O’Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s esophagus in primary care: cohort study. BMJ 2010; 341:c4372. doi:10.1136/bmj.c4372

14. Iqbal U, Siddique O, Ovalle A, Anwar H, Moss SF. Safety and effi cacy of a minimally invasive cell sampling device (‘Cytosponge’) in the diagnosis of esophageal pathology: a systematic review. Eur J Gastroenterol Hepatol 2018; 30(11):1261–1269. doi:10.1097/MEG.0000000000001210

15. Moinova HR, LaFramboise T, Lutterbaugh JD, et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus. Sci Transl Med 2018; 10(424):eaao5848. doi:10.1126/scitranslmed.aao5848

16. Shariff MK, Varghese S, O’Donovan M, et al. Pilot randomized crossover study comparing the effi cacy of transnasal disposable endosheath with standard endoscopy to detect Barrett’s esophagus. Endoscopy 2016; 48(2):110–116. doi:10.1055/s-0034-1393310

17. Peters Y, Schrauwen RWM, Tan AC, Bogers SK, de Jon B, Siersema PD. Detection of Barrett’s oesophagus through exhaled breath using an electronic nose device. Gut 2020; 69(7):1169–1172. doi:10.1136/gutjnl-2019-320273

18. Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett’s esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007; 99(7):545–557. doi:10.1093/jnci/djk112

19. Kubo A, Levin TR, Block G, et al. Dietary antioxidants, fruits, and vegetables and the risk of Barrett’s esophagus. Am J Gastroenterol 2008; 103(7):1614–1624. doi:10.1111/j.1572-0241.2008.01838.x

20. Kubo A, Block G, Quesenberry CP Jr, Buffl er P, Corley DA. Effects of dietary fi ber, fats, and meat intakes on the risk of Barrett’s esophagus. Nutr Cancer 2009; 61(5):607–616. doi:10.1080/01635580902846585

21. Graham DY, Schwartz JT, Cain GD, Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 1982; 82(2):228–231. pmid:7054024

22. Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17(7):855– 883. doi:10.6004/jnccn.2019.0033

23. Cuellar SL, Carter BW, Macapinlac HA, et al. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol 2014; 9(8):1202–1206. doi:10.1097/JTO.0000000000000222

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

CONTENIDOS RELACIONADOS
AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024